A multicenter collaboration has identified a potential new treatment for an aggressive sarcoma arising in the nerves. The ...

Onco-Innovations Limited has announced promising results from its licensed technology of PNKP inhibitors, which enhance the ...

Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations, disease ...

Work at Aston University has led to the identification of tissue transglutaminase (TGM2) inhibitors potentially useful for the treatment of fibrosis, thrombosis, cancer, AIDS, inflammation, transplant ...

Tyligand Bioscience Ltd. has prepared and tested tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer.

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

Researchers leverage artificial intelligence and machine learning techniques to investigate which among thousands of ...

Panelists discuss how the inclusion of ibrutinib on the Inflation Reduction Act (IRA) negotiated drug price list could make it a more economically attractive first-line option, potentially influencing ...

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...